Forecast for scni stock

The forecast for Scinai Immunotherapeutics Ltd. (SCNI) stock is as follows: 1. **Analyst Ratings and Price Targets**: - There are no analyst ratings or price targets available for SCNI at the moment. 2. **Stock Performance and Predictions**: - SCNI's stock has experienced volatility, with a recent trading range between $3.77 and $4.15. - The stock is expected to remain within this range, with a predicted price range between $3.88 and $4.29 over the next ten trading days. 3. **Market Sentiment**: - The sentiment towards SCNI is cautious, with recent news highlighting the company's efforts to address the NanoAb pipeline and its CDMO business. - There are no current buy or sell signals from technical indicators, and the stock is not considered to be oversold or overbought. 4. **Company Fundamentals**: Scinai is focused on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices business unit. The company has recently announced promising results in an in-vivo proof-of-concept psoriatic human skin model and has been actively advancing its NanoAb pipeline. In conclusion, the current sentiment towards SCNI stock is cautious, with analysts suggesting a lack of strong buy or sell signals based on technical indicators and the stock's recent performance. However, the company's efforts to advance its pipeline and CDMO business suggest potential for growth, and investors should consider these factors along with broader market and industry trends when evaluating SCNI stock.